Giiant Pharma is a Canadian, preclinical-stage biotech that designs gut-restricted small-molecule drug therapeutics using a proprietary Precision Delivery technology that leverages the gut microbiota to bioactivate poorly-absorbable prodrug therapeutics. Its lead program, GT-2108, is an orally administered, gut-restricted, colon-specific PDE4 inhibitor prodrug intended for moderate-to-severe ulcerative colitis. The company says GT-2108 offers vastly improved drug tolerability and enhanced therapeutic effect. Giiant will use the financing to pursue an IND-enabling preclinical program for GT-2108 with the aim of an IND filing by Q2 2024. The company is currently in discussions with potential pharmaceutical partners to co-develop and accelerate the GT-2108 program. The announcement identifies the company as headquartered in Montreal. Giiant Pharma is a preclinical-stage biotech company based in Montreal that designs gut-restricted, tissue-specific small-molecule drug therapeutics using its proprietary Precision Delivery technology platform. Its lead program, GT-2108, is a microbiota-activated PDE4 inhibitor prodrug designed to improve drug tolerability and enhance therapeutic effect for moderate-to-severe ulcerative colitis. The company plans to use recently raised funds to initiate an IND-enabling preclinical program for GT-2108. Giiant’s pipeline targets various biological mechanisms in gastroenterology with an emphasis on localized activity in the gut. Leadership includes CEO Maxime Ranger, Chief Development Officer Dr. Elizabeth Kwong, and Chief Clinical Officer Patrick Colin. The company is positioned as a preclinical-stage therapeutics developer focused on advancing its lead candidate toward clinical entry.

Total raised

$12M

Funding rounds

2

Latest round

Equity

Latest activity

Jan 2023